NTAGI approves Serum Institute’s Covovax vaccine for 12 to 17 age group
NEW DELHI , APRIL 29 : The National Technical Advisory Group on Immunization (NTAGI) on Friday approved Serum Institute of India’s Covid-19 vaccine Covovax for the 12-17 age group.
The government panel decided to include Covovax in India’s immunisation drive against Covid-19. This makes Covovax another option for vaccines for children between the ages of 12-17 years.
India;s vaccination drive for children between the ages of 12 and 14 years began from March 16 with Biological E’s Corbevax.
Earlier, the Drugs Controller General of India (DCGI) had approved Covovax for restricted use in emergency situations in adults on December 28 and in children in the 12-17 age group, subject to certain conditions,
The Serum Institute had recently written to the Health Ministry, seeking Covovax’s inclusion in the inoculation drive.
India’s drugs regulator approves phase-3 trial of Covid vaccine covovax.
-The India Today
